{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,11,4]],"date-time":"2022-11-04T00:51:02Z","timestamp":1667523062702},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2021,3,18]],"date-time":"2021-03-18T00:00:00Z","timestamp":1616025600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,3,18]],"date-time":"2021-03-18T00:00:00Z","timestamp":1616025600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["HNO"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1007\/s00106-021-01018-z","type":"journal-article","created":{"date-parts":[[2021,3,18]],"date-time":"2021-03-18T19:38:11Z","timestamp":1616096291000},"page":"868-877","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Dupilumab besitzt einen Zusatznutzen f\u00fcr die Behandlung der chronischen Rhinosinusitis mit Nasenpolypen"],"prefix":"10.1007","volume":"69","author":[{"given":"L.","family":"Klimek","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Chaker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Deitmer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S. K.","family":"Plontke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Wollenberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Bousquet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Bachert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,3,18]]},"reference":[{"issue":"9","key":"1018_CR1","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1111\/j.1398-9995.2011.02646.x","volume":"66","author":"D Hastan","year":"2011","unstructured":"Hastan\u00a0D, Fokkens\u00a0WJ, Bachert\u00a0C, Newson\u00a0RB, Bislimovska\u00a0J, Bockelbrink\u00a0A et al (2011) Chronic rhinosinusitis in Europe-\u2014an underestimated disease. A GA\u00b2LEN study. Allergy 66(9):1216\u20131223. https:\/\/doi.org\/10.1111\/j.1398-9995.2011.02646.x","journal-title":"Allergy"},{"issue":"2","key":"1018_CR2","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1111\/all.13042","volume":"72","author":"AG Hirsch","year":"2017","unstructured":"Hirsch\u00a0AG, Stewart\u00a0WF, Sundaresan\u00a0AS, Young\u00a0AJ, Kennedy\u00a0TL, Greene\u00a0SJ et al (2017) Nasal and sinus symptoms and chronic rhinosinusitis in a\u00a0population-based sample. Allergy 72(2):274\u2013281. https:\/\/doi.org\/10.1111\/all.13042","journal-title":"Allergy"},{"issue":"1","key":"1018_CR3","doi-asserted-by":"publisher","first-page":"43","DOI":"10.4193\/Rhin18.061","volume":"57","author":"A Ostovar","year":"2019","unstructured":"Ostovar\u00a0A, Fokkens\u00a0WJ, Vahdat\u00a0K, Raeisi\u00a0A, Mallahzadeh\u00a0A, Farrokhi\u00a0S (2019) Epidemiology of chronic rhinosinusitis in Bushehr, southwestern region of Iran: a\u00a0GA2LEN study. Rhinology 57(1):43\u201348. https:\/\/doi.org\/10.4193\/Rhin18.061","journal-title":"Rhinology"},{"issue":"5","key":"1018_CR4","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1111\/all.12577","volume":"70","author":"JB Shi","year":"2015","unstructured":"Shi\u00a0JB, Fu\u00a0QL, Zhang\u00a0H, Cheng\u00a0L, Wang\u00a0YJ, Zhu\u00a0DD et al (2015) Epidemiology of chronic rhinosinusitis: results from a\u00a0cross-sectional survey in seven Chinese cities. Allergy 70(5):533\u2013539. https:\/\/doi.org\/10.1111\/all.12577","journal-title":"Allergy"},{"issue":"Suppl S29","key":"1018_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4193\/Rhin20.600","volume":"58","author":"WJ Fokkens","year":"2020","unstructured":"Fokkens\u00a0WJ, Lund\u00a0VJ, Hopkins\u00a0C, Hellings\u00a0PW, Kern\u00a0R, Reitsma\u00a0S et\u00a0al (2020) European position paper on rhinosinusitis and nasal polyps 2020. Rhinology 58(Suppl S29):1\u2013464. https:\/\/doi.org\/10.4193\/Rhin20.600","journal-title":"Rhinology"},{"issue":"3","key":"1018_CR6","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/j.otohns.2007.07.021","volume":"137","author":"RM Rosenfeld","year":"2007","unstructured":"Rosenfeld\u00a0RM (2007) Clinical practice guideline on adult sinusitis. Otolaryngol Head Neck Surg 137(3):365\u2013377. https:\/\/doi.org\/10.1016\/j.otohns.2007.07.021","journal-title":"Otolaryngol. Head Neck Surg."},{"issue":"1","key":"1018_CR7","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1007\/s00106-017-0401-5","volume":"66","author":"BA Stuck","year":"2018","unstructured":"Stuck\u00a0BA, Beule\u00a0A, Jobst\u00a0D, Klimek\u00a0L, Laudien\u00a0M, Lell\u00a0M et al (2018) Guideline for \u201crhinosinusitis\u201d-long version : S2k guideline of the German College of General Practitioners and Family Physicians and the German Society for Oto-Rhino-Laryngology, Head and Neck Surgery. HNO 66(1):38\u201374. https:\/\/doi.org\/10.1007\/s00106-017-0401-5","journal-title":"HNO"},{"key":"1018_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13601-019-0303-6","volume":"10","author":"V Hox","year":"2020","unstructured":"Hox\u00a0V, Lourijsen\u00a0E, Jordens\u00a0A, Aasbjerg\u00a0K, Agache\u00a0I, Alobid\u00a0I et al (2020) Benefits and harm of systemic steroids for short- and long-term use in rhinitis and rhinosinusitis: an EAACI position paper. Clin Transl Allergy 10:1. https:\/\/doi.org\/10.1186\/s13601-019-0303-6","journal-title":"Clin Transl Allergy"},{"issue":"2","key":"1018_CR9","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1007\/s40629-017-0048-5","volume":"27","author":"M Koennecke","year":"2018","unstructured":"Koennecke\u00a0M, Klimek\u00a0L, Mullol\u00a0J, Gevaert\u00a0P, Wollenberg\u00a0B (2018) Subtyping of polyposis nasi: phenotypes, endotypes and comorbidities. Allergo J Int 27(2):56\u201365. https:\/\/doi.org\/10.1007\/s40629-017-0048-5","journal-title":"Allergo J Int"},{"issue":"5","key":"1018_CR10","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1016\/j.jaci.2015.12.1324","volume":"137","author":"P Tomassen","year":"2016","unstructured":"Tomassen\u00a0P, Vandeplas\u00a0G, Van Zele\u00a0T, Cardell\u00a0L\u2011O, Arebro\u00a0J, Olze\u00a0H et al (2016) Inflammatory endotypes of chronic rhinosinusitis based on cluster analysis of biomarkers. J\u00a0Allergy Clin Immunol 137(5):1449\u20131456.e4. https:\/\/doi.org\/10.1016\/j.jaci.2015.12.1324","journal-title":"J Allergy Clin Immunol"},{"issue":"10","key":"1018_CR11","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1136\/thorax.57.10.875","volume":"57","author":"RH Green","year":"2002","unstructured":"Green\u00a0RH, Brightling\u00a0CE, Woltmann\u00a0G, Parker\u00a0D, Wardlaw\u00a0AJ, Pavord\u00a0ID (2002) Analysis of induced sputum in adults with asthma: identification of subgroup with isolated sputum neutrophilia and poor response to inhaled corticosteroids. Thorax 57(10):875\u2013879. https:\/\/doi.org\/10.1136\/thorax.57.10.875","journal-title":"Thorax"},{"key":"1018_CR12","doi-asserted-by":"publisher","DOI":"10.1055\/a-1200-1830","author":"L Klimek","year":"2020","unstructured":"Klimek\u00a0L, Spielhaupter\u00a0M, Alali\u00a0A, Cichy\u00a0M, Huppertz\u00a0T, Hagemann\u00a0J (2020) Eosinophilie unter dupilumab bei chronischer rhinosinusitis mit polyposis nasi\u00a0und\u00a0asthma bronchiale. Laryngorhinootologie. https:\/\/doi.org\/10.1055\/a-1200-1830","journal-title":"Laryngorhinootologie"},{"key":"1018_CR13","unstructured":"GINA Global Strategy for Asthma Management and Prevention (2019 update). https:\/\/ginasthma.org\/wp-content\/uploads\/2019\/06\/GINA-2019-main-report-June-2019-wms.pdf. Zugegriffen: 12.\u00a0M\u00e4rz 2021"},{"issue":"5","key":"1018_CR14","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1055\/a-1148-3553","volume":"99","author":"L Klimek","year":"2020","unstructured":"Klimek\u00a0L, F\u00f6rster-Ruhrmann\u00a0U, Becker\u00a0S, Chaker\u00a0A, Huppertz\u00a0T, Deitmer\u00a0T et al (2020) Stellungnahme zur Anwendung von Glukokortikosteroiden bei entz\u00fcndlichen Erkrankungen der oberen Atemwege (u.\u202fa. allergische Rhinitis\/chronische Rhinosinusitis) w\u00e4hrend der aktuellen COVID-19-Pandemie \u2013 Empfehlungen des \u00c4rzteverbandes Deutscher Allergologen (AeDA), des Deutschen Berufsverbandes der HNO-\u00c4rzte (BVHNO) und der AGs Klinische Immunologie, Allergologie und Umweltmedizin und Rhinologie und Rhinochirurgie der Deutschen Gesellschaft f\u00fcr HNO-Heilkunde, Kopf- und Halschirurgie (DGHNO-KHC). Laryngorhinootologie 99(5):280\u2013281. https:\/\/doi.org\/10.1055\/a-1148-3553","journal-title":"Laryngorhinootologie"},{"issue":"Suppl 1","key":"1018_CR15","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1002\/alr.21694","volume":"6","author":"RR Orlandi","year":"2016","unstructured":"Orlandi\u00a0RR, Kingdom\u00a0TT, Hwang\u00a0PH (2016) International consensus statement on allergy and rhinology: rhinosinusitis executive summary. Int Forum Allergy Rhinol 6(Suppl 1):S3\u2013S21. https:\/\/doi.org\/10.1002\/alr.21694","journal-title":"Int Forum Allergy Rhinol"},{"issue":"1","key":"1018_CR16","doi-asserted-by":"publisher","first-page":"3","DOI":"10.4193\/Rhin15.079","volume":"54","author":"V Pundir","year":"2016","unstructured":"Pundir\u00a0V, Pundir\u00a0J, Lancaster\u00a0G, Baer\u00a0S, Kirkland\u00a0P, Cornet\u00a0M et al (2016) Role of corticosteroids in functional endoscopic sinus surgery-\u2014a systematic review and meta-analysis. Rhinology 54(1):3\u201319. https:\/\/doi.org\/10.4193\/Rhin15.079","journal-title":"Rhinology"},{"issue":"2","key":"1018_CR17","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1111\/all.13556","volume":"74","author":"J Voorham","year":"2018","unstructured":"Voorham\u00a0J, Xu\u00a0X, Price\u00a0DB, Golam\u00a0S, Davis\u00a0J, Zhi Jie\u00a0LJ et\u00a0al (2018) Healthcare resource utilization and costs associated with incremental systemic corticosteroid exposure in asthma. Allergy 74(2):273\u2013283. https:\/\/doi.org\/10.1111\/all.13556","journal-title":"Allergy"},{"issue":"5","key":"1018_CR18","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1007\/s00106-015-0008-7","volume":"63","author":"H Kirsche","year":"2015","unstructured":"Kirsche\u00a0H, Klimek\u00a0L (2015) ASS-Intoleranz-Syndrom und persistierende Rhinosinusitis : Differentialdiagnostik und Therapie. HNO 63(5):357\u2013363. https:\/\/doi.org\/10.1007\/s00106-015-0008-7","journal-title":"HNO"},{"issue":"4","key":"1018_CR19","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1016\/j.iac.2009.07.008","volume":"29","author":"L Klimek","year":"2009","unstructured":"Klimek\u00a0L, Pfaar\u00a0O (2009) Aspirin intolerance: does desensitization alter the course of the disease? Immunol Allergy Clin North Am 29(4):669\u2013675. https:\/\/doi.org\/10.1016\/j.iac.2009.07.008","journal-title":"Immunol Allergy Clin North Am"},{"issue":"1","key":"1018_CR20","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1111\/all.13599","volume":"74","author":"ML Kowalski","year":"2019","unstructured":"Kowalski\u00a0ML, Agache\u00a0I, Bavbek\u00a0S, Bakirtas\u00a0A, Blanca\u00a0M, Bochenek\u00a0G et al (2019) Diagnosis and management of NSAID-Exacerbated Respiratory Disease (N-ERD)-a EAACI position paper. Allergy 74(1):28\u201339. https:\/\/doi.org\/10.1111\/all.13599","journal-title":"Allergy"},{"issue":"4","key":"1018_CR21","doi-asserted-by":"publisher","first-page":"307","DOI":"10.4193\/Rhin17.027","volume":"56","author":"C Hopkins","year":"2018","unstructured":"Hopkins\u00a0C, Surda\u00a0P, Bast\u00a0F, Hettige\u00a0R, Walker\u00a0A, Hellings\u00a0PW (2018) Prevention of chronic rhinosinusitis. Rhinology 56(4):307\u2013315. https:\/\/doi.org\/10.4193\/Rhin17.027","journal-title":"Rhinology"},{"issue":"2","key":"1018_CR22","doi-asserted-by":"publisher","first-page":"155","DOI":"10.4193\/Rhin17.115","volume":"56","author":"SJ Kilty","year":"2018","unstructured":"Kilty\u00a0SJ, Lasso\u00a0A, Mfuna-Endam\u00a0L, Desrosiers\u00a0MY (2018) Case-control study of endoscopic polypectomy in clinic (EPIC) versus endoscopic sinus surgery for chronic rhinosinusitis with polyps. Rhinology 56(2):155\u2013157. https:\/\/doi.org\/10.4193\/Rhin17.115","journal-title":"Rhinology"},{"issue":"2","key":"1018_CR23","doi-asserted-by":"publisher","first-page":"117","DOI":"10.4193\/Rhin16.023","volume":"54","author":"L Rudmik","year":"2016","unstructured":"Rudmik\u00a0L, Soler\u00a0ZM, Hopkins\u00a0C, Schlosser\u00a0RJ, Peters\u00a0A, White\u00a0AA et\u00a0al (2016) Defining appropriateness criteria for endoscopic sinus surgery during management of uncomplicated adult chronic rhinosinusitis: a\u00a0RAND\/UCLA appropriateness study. Rhinology 54(2):117\u2013128. https:\/\/doi.org\/10.4193\/Rhin16.023","journal-title":"Rhinology"},{"issue":"5","key":"1018_CR24","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1080\/1744666X.2017.1298443","volume":"13","author":"NA Gandhi","year":"2017","unstructured":"Gandhi\u00a0NA, Pirozzi\u00a0G, Graham\u00a0NMH (2017) Commonality of the IL-4\/IL-13 pathway in atopic diseases. Expert Rev Clin Immunol 13(5):425\u2013437. https:\/\/doi.org\/10.1080\/1744666X.2017.1298443","journal-title":"Expert Rev Clin Immunol"},{"key":"1018_CR25","unstructured":"Sanofi-Aventis_Deutschland_GmbH. Dupixent\u00ae 300\u202fmg Injektionsl\u00f6sung in einer Fertigspritze, R.L.S. GmbH \u2013 Fachinformation. Rote Liste Service GmbH Frankfurt. 2020:p. 21."},{"issue":"8","key":"1018_CR26","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1055\/a-1197-0136","volume":"99","author":"L Klimek","year":"2020","unstructured":"Klimek\u00a0L, F\u00f6rster-Ruhrmann\u00a0U, Becker\u00a0S, Chaker\u00a0A, Strieth\u00a0S, Hoffmann\u00a0TK et al (2020) Positionspapier: Anwendung von Biologika bei chronischer Rhinosinusitis mit Polyposis nasi (CRSwNP) im deutschen Gesundheitssystem \u2013 Empfehlungen des \u00c4rzteverbandes Deutscher Allergologen (AeDA) und der AGs Klinische Immunologie, Allergologie und Umweltmedizin und Rhinologie und Rhinochirurgie der Deutschen Gesellschaft f\u00fcr HNO-Heilkunde, Kopf- und Halschirurgie (DGHNOKHC). Laryngorhinootologie 99(8):511\u2013527. https:\/\/doi.org\/10.1055\/a-1197-0136","journal-title":"Laryngorhinootologie"},{"key":"1018_CR27","unstructured":"(2019) A Controlled Clinical Study of Dupilumab in Patients With Bilateral Nasal Polyps (SINUS-24). Sanofi. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02912468. Zugegriffen: 9. M\u00e4rz 2020"},{"key":"1018_CR28","unstructured":"(2019) Controlled clinical study of dupilumab in patients with nasal polyps (SINUS-52). Sanofi. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02898454. Zugegriffen: 9. M\u00e4rz 2020"},{"issue":"6","key":"1018_CR29","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1055\/a-1164-9696","volume":"99","author":"L Klimek","year":"2020","unstructured":"Klimek\u00a0L, Becker\u00a0S, Buhl\u00a0R, Chaker\u00a0AM, Huppertz\u00a0T, Hoffmann\u00a0TK et al (2020) Positionspapier: Empfehlungen zur Behandlung der chronischen Rhinosinusitis w\u00e4hrend der COVID-19-Pandemie im deutschen Gesundheitssystem \u2013 Empfehlungen des \u00c4rzteverbandes Deutscher Allergologen (AeDA) und der Deutschen Gesellschaft f\u00fcr HNO-Heilkunde, Kopf- und Halschirurgie (DGHNO-KHC) \u2013 Diese Empfehlungen basieren auf dem EAACI Positionspapier \u201cTreatment of chronic RhinoSinusitis with nasal polyps (CRSwNP) in the COVID-19 pandemics \u2013 An EAACI Position Paper\u201d, Allergy, 2020 und wurden auf die Situation im deutschen Gesundheitswesen angepasst. Laryngorhinootologie 99(6):356\u2013364. https:\/\/doi.org\/10.1055\/a-1164-9696","journal-title":"Laryngorhinootologie"},{"key":"1018_CR30","doi-asserted-by":"publisher","DOI":"10.1111\/all.14467","author":"L Klimek","year":"2020","unstructured":"Klimek\u00a0L, Hagemann\u00a0J, Alali\u00a0A, Spielhaupter\u00a0M, Huppertz\u00a0T, H\u00f6rmann\u00a0K et al (2020) Telemedicine allows quantitative measuring of olfactory dysfunction in COVID-19. Allergy. https:\/\/doi.org\/10.1111\/all.14467","journal-title":"Allergy"},{"issue":"7","key":"1018_CR31","doi-asserted-by":"publisher","first-page":"255","DOI":"10.5414\/ALX02166","volume":"43","author":"L Klimek","year":"2020","unstructured":"Klimek\u00a0L, Pfaar\u00a0O, Worm\u00a0M (2020) Anwendung von Biologika bei allergischen und Typ-2-entz\u00fcndlichen Erkrankungen in der aktuellen COVID-19-Pandemie - ein Positionspapier von AeDA, DGAKI, GPA, \u00d6GAI, LGAI, \u00d6GP, ARIA und EAACI. Use of biologicals in allergic and type\u20112 inflammatory diseases in times of the current COVID-19 pandemic\u2014Position paper of AeDA, DGAKI, GPA, \u00d6GAI, LGAI, \u00d6GP, ARIA und EAACI. AL 43(7):255","journal-title":"AL"}],"container-title":["HNO"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00106-021-01018-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00106-021-01018-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00106-021-01018-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,25]],"date-time":"2021-10-25T11:14:38Z","timestamp":1635160478000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00106-021-01018-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,18]]},"references-count":31,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["1018"],"URL":"https:\/\/doi.org\/10.1007\/s00106-021-01018-z","relation":{},"ISSN":["0017-6192","1433-0458"],"issn-type":[{"value":"0017-6192","type":"print"},{"value":"1433-0458","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,18]]},"assertion":[{"value":"9 December 2020","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"L.\u00a0Klimek berichtet \u00fcber Zusch\u00fcsse und\/oder Honorare von Allergopharma, MEDA\/Mylan, HAL Allergie, ALK-Abell\u00f3, LETI Pharma, Stallergenes, Quintiles, Sanofi, ASIT Biotech, Lofarma, Allergy Therapeut., AstraZeneca, GSK, Inmunotk au\u00dferhalb der eingereichten Arbeit, sowie Mitgliedschaft bei folgenden Organisationen: AeDA, DGHNO, Deutsche Akademie f\u00fcr Allergologie und klinische Immunologie, HNO-BV GPA, EAACI. A.\u00a0Chaker f\u00fchrt \u00fcber die Technische Universit\u00e4t M\u00fcnchen Beratungsleistungen (z.\u202fB. Advisory Boards, DSMBs), Vortr\u00e4ge oder weitere Aktivit\u00e4ten f\u00fcr Allergopharma, ALK-Abell\u00f3, AstraZeneca, GSK, HAL Allergy, Mundipharma, Nexter, Immunotek, Lofarma, SanofiGenzyme und Regeneron durch; hat klinische Studien oder Forschungsgelder \u00fcber die Technische Universit\u00e4t M\u00fcnchen erhalten von ALK-Abell\u00f3, Allergopharma, AstraZeneca, Bencard\/Allergen Therapeutics, ASIT Biotech, GSK, Novartis, Roche, und Zeller AG, ferner Forschungsmittel erhalten vom Umweltbundesamt der Bundesrepublik Deutschland, EIT Health und DZL (BMBF). A.\u00a0Chaker hat ferner Honorare und Reisekostenerstattungen erhalten vom Bayerischen \u00c4rzteblatt, der Deutschen Gesellschaft f\u00fcr Allergologie und klinische Immunologie (DGAKI) und der European Academy of Allergy and Clinical Immunology. B.\u00a0Wollenberg hat Honorare und\/oder Forschungsgelder von MSD, Sanofi, AstraZeneca, Novartis und BMS Adboard au\u00dferhalb der vorliegenden Arbeit erhalten. C.\u00a0Bousquet berichtet \u00fcber Zusch\u00fcsse und\/oder Honorare von Chiesi, Cipla, Hikma, Menarini, Mundipharma, Mylan, Novartis, Purina, Sanofi-Aventis, Takeda, Teva, Uriach, andere von KYomed INNOV au\u00dferhalb der vorliegenden Arbeit. C.\u00a0Bachert erhielt Honorare und\/oder Forschungsgelder von Sanofi, Novartis, GSL und AstraZeneca au\u00dferhalb der vorliegenden Arbeit. T.\u00a0Deitmer und S.K.\u00a0Plontke geben an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}